Generative AI Collaboration Advances mRNA Medicine Innovations

Moderna, Inc. and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare.

Moderna is a digital-first company that has leveraged the power of machine learning since its beginnings.

This strong data foundation and its robust learning culture position the Company to responsibly and seamlessly integrate generative AI into its operations and capitalize on next-generation AI innovation.

The organizations began their collaboration in early 2023 by launching Moderna's instance of ChatGPT, called mChat, internally built on top of OpenAI's API.

With more than 80% internal adoption since its debut, this initial success accelerated an AI culture that led to the deployment of ChatGPT Enterprise and its enhanced capabilities such as Advanced Analytics, Image Generation and GPTs.

These GPTs are now embedded across Moderna's business functions - from legal, to research, to manufacturing, to commercial - and are purpose-built as assistants that work beside Moderna's employees, augmenting their roles through personalized support.

With these tools serving as an extension to Moderna's team, the Company can advance its mission to deliver the greatest possible impact to people through mRNA medicines.

Stéphane Bancel, Chief Executive Officer of Moderna, commented in a press release on April 24, 2024, "Moderna has an ambitious plan to launch multiple products over the next few years, and collaborations with companies like OpenAI are critical to our ability to scale and maximize our impact on patients."